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NEWS AND PERSPECTIVES
Introduction
The latest World Health Organization (WHO)
figures (June 17, 2009) show that 88 countries
have officially reported 39,620 cases of influenza
A (H1N1) infection, including 167 deaths.1 The
rapid worldwide spread and the apparent lack of
preexisting immunity in humans qualify this as 
a pandemic virus. The identification of this novel
virus in the beginning of April 2009 and sub-
sequent international screening programs have
demonstrated that the virus is able to spread from
human to human. These data are sufficient to state
that we are currently experiencing an influenza
pandemic. WHO raised the pandemic influenza
alert to phase 6 on June 10, 2009.
2009 H1N1 Virus
The last influenza pandemic was in 1968; H1N1
is therefore the first opportunity to study a pan-
demic outbreak in real time with all the modern
analytical methods that have been developed 
in recent decades. Indeed, data have been gener-
ated with astonishing rapidity. Full-length viral
genome sequences from around the world have
been published in public-access databases. The
internet has been extensively used to keep track
of the spread of the virus. Large community 
efforts have been made to restrict the spread of
the virus right from the start of the pandemic. In
this issue of the Journal of the Formosan Medical
Association, Chang et al present one of the first 
reviews about this novel virus.2 The 2009 H1N1
virus is currently presenting itself as a relatively
mild form of influenza, with common symptoms
such as cough, sore throat, and headache. A char-
acteristic of the 2009 H1N1 infection is the fre-
quent occurrence of diarrhea and vomiting, which
is unusual for seasonal influenza. Also, present
data seem to show that younger people are more
susceptible to infection. However, more data are
needed to determine the cause of this, as it may
very well be the result of a bias in sampling or a
bias in the spread of the virus among the human
population. An initial study reported that hospi-
talization was needed in almost 10% of cases, and
the mortality rate was about 0.4%.3 Based on the
officially reported cases, the current mortality
rate is approximately 0.4%. Because of the mild
pathogenicity, most infected persons will not be
reported, and therefore these numbers are cer-
tainly a huge overestimation. One possible excep-
tion, reported by WHO on June 10, 2009, is that
the infection might be more severe in some iso-
lated groups of the Inuit population in Canada.
Obviously, more surveys and further analysis are
needed to determine the underlying mechanisms.
Surprising Sequence Data
Sequence data for the new virus became quickly
available in public-access databases and showed
remarkable characteristics. The H1N1 virus has 
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a genome derived mostly from North American
swine influenza A, but with the NA and M pro-
teins from the Eurasian swine lineage.2,3 This
particular organization is unique and is especially
interesting since it combines a Eurasian and
American line. This combination has not been
found previously in pigs, only in humans and 
a small isolated swine herd in Alberta that was
likely to have been infected by humans.4 How-
ever, Smith et al5 very recently demonstrated that
it is likely that the virus has been in pigs for sev-
eral years. Fortunately, the current spread in hu-
mans has been detected relatively early, indicating
that the surveillance of the human population is
adequate to pick up pandemic influenza.
Another surprise from the sequence data is
that the virus seems unusually stable in terms of
genome evolution.3,6 In the context of vaccine
development, this is obviously good news. The
currently produced vaccines are based on the orig-
inal viruses and are therefore more likely to be
effective. However, it is not clear what this means
for the virus–host interaction. It is still possible
that this is merely a founder effect. Similar viral
sequences from around the world do not mean a
lot if it requires only one airplane to transport
the virus to another location. But, if this lack of
viral evolution remains during the pandemic, then
there is apparently little selection pressure on the
H1N1 virus to change. This may be related to the
limited preexisting immunity. People are infected
by this virus, and before the host can mount an
appropriate immune response, the virus has prop-
agated sufficiently to reach high enough viral loads
to facilitate transmission and spreading in the pop-
ulation. This is in contrast to seasonal influenza,
which needs to escape from preexisting immu-
nity in the host.
In this respect, it is interesting that the virus
has truncated versions of PB1-F2 and NS1 (see the
review of Chang et al2 for more details). These
two proteins are associated with high virulence
because of their suppressive effect on the host
immune system. The PB1-F2 protein has been
shown to specifically target and destroy alveolar
macrophages (reviewed by Coleman7); the NS1
protein inhibits type 1 interferon production,8
and may play a role in the suppression of innate
immunity by acting as an RNAi suppressor.9
2009 Influenza A H1N1 and Avian H5N1
With all the focus on the new H1N1 virus, we
should not forget about the highly pathogenic
influenza A H5N1 virus. The H5N1 picture is quite
different from that of H1N1. The avian influenza
(H5N1) virus incidentally infects humans but with
high mortality. Fortunately, the H5N1 virus has
not developed into a variant that can spread from
human to human.10–12 However, with the world-
wide spread and high infection rate of H1N1, the
risk exists of reassortment between the H5N1 and
H1N1 viruses, which could result in a deadly and
infectious virus. An alternative and perhaps more
likely reassortment between the pandemic and
seasonal H1N1 viruses is another worrying pos-
sibility, as the current seasonal H1N1 virus is re-
sistant to oseltamivir (reviewed by the Novel
Swine-Origin Influenza A (H1N1) Virus investiga-
tion Team3). The new 2009 influenza A (H1N1)
virus is already resistant to adamantine and a
novel reassortment virus could be multidrug-
resistant.
In conclusion, we are currently in a phase 6
pandemic with a novel, relatively mild influenza
virus (H1N1). Although we have not been able
to stop this pandemic, worldwide efforts have re-
sulted in the rapid identification and characteri-
zation of the virus. Continual monitoring and
surveillance of the H1N1 virus is required to en-
able us to respond to any change in the virus that
could influence its pathogenicity, resistance to
antiviral drugs, or sensitivity to the vaccines that
are currently being developed.
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